

Date: January 3, 2002

Page 1 of 1

Form PTO-1449 (REV. 07/01)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. HSS-022XX		APPLICATION NO. 09/937,191	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)							
				APPLICANT: Walter Schubert			
				FILING DATE: September 21, 2001		GROUP:	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE*
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
		WO 98 44923* ✓	10/15/1998	WIPO			X
		EP 0 167 936 A2*	01/15/1986	EPO			X
my		GB 1 540 019** ✓	02/07/1979	Great Britain			X
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)							
my		Effect of ubenimex on the immune system of patients with hematological malignancies. T. Yamazaki et al., <i>Biomed & Pharmacother.</i> (1991), 45, 105-112.*					
		Potent Homophthalimide-Type Inhibitors of B16F10 L5 Mouse Melanoma Cell Invasion, H. Kagechika et al., <i>Biol. Pharm. Bull.</i> (1999), 22(9), 1010-1012.* ✓					
		Inhibition of Alanyl Aminopeptidase Induces MAP-Kinase p42 ERK2 in the Human T Cell Line KARPAS-299. U. Lendeckel et al., <i>Biochemical and Biophysical Research Communications</i> , (1998), 252(1), 5-9.*					
		Inhibition of tumor invasion and extracellular matrix degradation by ubenimex (bestatin). J. Yoneda et al., <i>Clinical & Experimental Metastasis</i> , (1992), 10(1), 49-59.**					
		Aminopeptidase Inhibitor Ubenimex (Bestatin) Inhibits the Growth of Human Choriocarcinoma in Nude Mice through its Direct Cytostatic Activity, K. Ino et al., <i>Anticancer Research</i> , (1995), 15, 2081-2087.** ✓					
		Antitumor Activity of Actinonin <i>in Vitro</i> and <i>in Vivo</i> , Y. Xu et al., <i>Clinical Cancer Research</i> , (Jan. 1998), 4, 171-176.**					
		Inhibition of Tumor Cell Invasion and Matrix Degradation by Aminopeptidase Inhibitors, H. Fujii et al., <i>Biol. Pharm. Bull.</i> , (1996), 19(1), 6-10.					
EXAMINER	Misra			DATE CONSIDERED 10-16-04			
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							